Prognostic factors of patient risk for failure to current treatment regimen.
| . | Group-specific adverse prognostic factors in addition to stage . | ||
|---|---|---|---|
| . | Established . | . | Candidate . |
| Abbreviations: EFS, event-free survival; MRD, minimal residual disease; CNS, central nervous system; BM, bone marrow; PB, peripheral blood; see Table 1 for additional abbreviations | |||
| LBL-pB | — | — | |
| LBL-T | Female > 10 years53 | EFS 60% | MRD monitoring55 |
| Del 6q54 | Relapse probability 46% | ||
| Burkitt | LDH > 2N >500 >1000 8,32 | LDH > 1000, pEFS 70% | MRD monitoring42 |
| CNS disease7,–9,29 | pEFS 65% | ||
| Age > 15 years7 | |||
| Polymorphism LT α-TNF56 | |||
| Nonresponse to prophase7,32 | |||
| Abber 13q37 | Survival 37% (n = 8) | ||
| Abber chrom 22 37 | Survival 0 (n = 7) | ||
| Gain 7 37 | |||
| Complex secondary aberrations38 | |||
| DLBCL | Female > 14 years of age53 | pEFS 50% | |
| PMLBL | LDH > 2N > 500 U/L35 | pEFS 40% | |
| Tumor size | |||
| ALCL | Mediastinal mass visceral involvement, skin57 | Progression-free 61% | MRD monitoring41,58 |
| Lymphohistiocytic variant14,36 | EFS 46% | ||
| Minimal systemic disease in BM, PB: > 10 copies NPM-ALK/10,000 copies abl41 | Cumulative incidence of relapse 71% | ||
| . | Group-specific adverse prognostic factors in addition to stage . | ||
|---|---|---|---|
| . | Established . | . | Candidate . |
| Abbreviations: EFS, event-free survival; MRD, minimal residual disease; CNS, central nervous system; BM, bone marrow; PB, peripheral blood; see Table 1 for additional abbreviations | |||
| LBL-pB | — | — | |
| LBL-T | Female > 10 years53 | EFS 60% | MRD monitoring55 |
| Del 6q54 | Relapse probability 46% | ||
| Burkitt | LDH > 2N >500 >1000 8,32 | LDH > 1000, pEFS 70% | MRD monitoring42 |
| CNS disease7,–9,29 | pEFS 65% | ||
| Age > 15 years7 | |||
| Polymorphism LT α-TNF56 | |||
| Nonresponse to prophase7,32 | |||
| Abber 13q37 | Survival 37% (n = 8) | ||
| Abber chrom 22 37 | Survival 0 (n = 7) | ||
| Gain 7 37 | |||
| Complex secondary aberrations38 | |||
| DLBCL | Female > 14 years of age53 | pEFS 50% | |
| PMLBL | LDH > 2N > 500 U/L35 | pEFS 40% | |
| Tumor size | |||
| ALCL | Mediastinal mass visceral involvement, skin57 | Progression-free 61% | MRD monitoring41,58 |
| Lymphohistiocytic variant14,36 | EFS 46% | ||
| Minimal systemic disease in BM, PB: > 10 copies NPM-ALK/10,000 copies abl41 | Cumulative incidence of relapse 71% | ||